Eli Lilly settles corrupt foreign practices complaint for $29.4mBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8694 (Published 27 December 2012) Cite this as: BMJ 2012;345:e8694
- Bob Roehr
- 1Washington, DC
The drug company Eli Lilly and Co has agreed to a $29.4m (£18.2m; €22.3m) settlement with the US Securities and Exchange Commission for violation of the US Foreign Corrupt Practices Act in a legal agreement signed on 20 December.1 The 1977 antibribery act made it “unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business.”
The settlement concerns activities by Lilly subsidiaries in Brazil, China, Poland, and Russia, some as early as 1994. Company headquarters learnt of some of the activities but didn’t do enough to halt them.
In Brazil the activities involved …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial